Stephen Michael Prescott
Physician in Salt Lake City, UT
License number
Utah 156548-8905
Issued Date
Sep 14, 1992
Expiration Date
Jan 31, 2018
Category
Physician
Type
Physician/Surgeon CS (Schedule 2-5)
Address
Address
Salt Lake City, UT
Personal information
See more information about Stephen Michael Prescott at radaris.comName
Address
Phone
860 2300, Salt Lake City, UT 84108
860 2300 E, Salt Lake City, UT 84108
Professional information
See more information about Stephen Michael Prescott at trustoria.com
Neuroprotection By Inhibition Of Diacyglycerol Kinase Epsilon Activity
Neuroprotection By Inhibition Of Diacyglycerol Kinase Epsilon Activity
US Patent:
2004013, Jul 8, 2004
Filed:
Sep 8, 2003
Appl. No.:
10/471116
Inventors:
Stephen Prescott - Salt Lake City UT, US
Matthew Topham - Salt Lake City UT, US
Nicolas Bazan - New Orleans LA, US
Elena B Rodriguez de Turco - New Orleans LA, US
Matthew Topham - Salt Lake City UT, US
Nicolas Bazan - New Orleans LA, US
Elena B Rodriguez de Turco - New Orleans LA, US
International Classification:
A61K049/00, C12Q001/48
US Classification:
435/015000, 424/009200
Abstract:
The present invention includes the characterization of the DGKe gene and the generation of screening methods for compounds that inhibit the function of DGKe. The DGK family of enzymes occupies a signaling crossroads since they catalyze the phosphorylation of DAG to produce PA. Both the substrate (DAG) and the product (PA) of this reaction are key factors in intracellular signaling, making the regulation of DGKe activity important to understand and control. DGKe -/- mice were also generated and studied to assist in understanding the function of DGKs in regulating cellular signaling. DGKe displays selectively for 20:4-DAG and is highly expressed in different areas of the brain, including Purkinje cells in the cerebellum, hippocampal interneurons, and the Pyramidal neurons in the CA3 region of the hippocampus.
Diacylglycerol Kinase Isoforms Epsilon And Zeta And Methods Of Use Thereof
Diacylglycerol Kinase Isoforms Epsilon And Zeta And Methods Of Use Thereof
US Patent:
5976875, Nov 2, 1999
Filed:
Apr 22, 1997
Appl. No.:
8/841483
Inventors:
Stephen M. Prescott - Salt Lake City UT
Michaeline Bunting - Salt Lake City UT
Wen Tang - Salt Lake City UT
Matthew Topham - Salt Lake City UT
Michaeline Bunting - Salt Lake City UT
Wen Tang - Salt Lake City UT
Matthew Topham - Salt Lake City UT
Assignee:
University of Utah - Salt Lake City UT
International Classification:
C12N 120, C07H 2104
US Classification:
435325
Abstract:
Two novel diacylglycerol kinase (DGK) isoforms are disclosed. The cDNA of one DGK isoform, designated DGK. epsilon. , is about 2. 6 kb in length. The DGK. epsilon. cDNA has an open reading frame encoding 567 amino acids and has a predicted molecular mass of 63 kDA. DAG kinase. epsilon. is highly selective for arachidonate-containing diacylglycerol (DAG) substrates. The cDNA of the second isoform, designated DGK. zeta. , is 3. 5 kb in length. The DGK. zeta. cDNA contains a single large open reading frame encoding a 928-amino acid protein with a predicted molecular mass of 103. 9 kDa. An alternatively spliced muscle specific species of DGK. zeta. , DGK. zeta. -2 is also disclosed and characterized. DGK. zeta. is localized to the nucleus. A lysine-rich region with homology to the MARCKS protein is shown to be necessary and sufficient to confer nuclear localization to DGK. zeta.
Method Of Screening For Agents That Regulate The Shedding Of Membrane Bound Proteins And Methods Of Use
Method Of Screening For Agents That Regulate The Shedding Of Membrane Bound Proteins And Methods Of Use
US Patent:
7241570, Jul 10, 2007
Filed:
Mar 22, 2002
Appl. No.:
10/471122
Inventors:
Stephen M. Prescott - Salt Lake City UT, US
Matthew Topham - Salt Lake City UT, US
Fumio Sakane - Sapporo, JP
Akinobu Taketomi - Nakatsu, JP
Matthew Topham - Salt Lake City UT, US
Fumio Sakane - Sapporo, JP
Akinobu Taketomi - Nakatsu, JP
Assignee:
University of Utah Research Foundation - Salt Lake City UT
International Classification:
C12Q 1/48, C12Q 1/68
US Classification:
435 6, 435 15
Abstract:
The present invention provides a method of screening for agents which may regulate or inhibit the activities of TACE and TGF-α. These agents may act by enhancing or inhibiting the activity of DGK-δ. An activity of DGK-δ is the enzymatic conversion of DAG to PA. The method includes contacting a cell or organism with a test agent determining the activity of DGK-δ within the cell. An agent with reduces or increases the activity of DGK may be used to regulate or inhibit the activity of TACE and TGF-α. Such agents can be used to treat diseases such as cancer where cell growth and division and inflamation are important factors.
Diacylglycerol Kinase Isoforms Epsilon And Zeta And Methods Of Use Thereof
Diacylglycerol Kinase Isoforms Epsilon And Zeta And Methods Of Use Thereof
US Patent:
6221658, Apr 24, 2001
Filed:
Aug 25, 1999
Appl. No.:
9/382911
Inventors:
Stephen M. Prescott - Salt Lake City UT
Michaeline Bunting - Salt Lake City UT
Wen Tang - Salt Lake City UT
Matthew Topham - Salt Lake City UT
Michaeline Bunting - Salt Lake City UT
Wen Tang - Salt Lake City UT
Matthew Topham - Salt Lake City UT
Assignee:
University of Utah Research Foundation - Salt Lake City UT
International Classification:
C12N 502, C12N 120, C07H 2104
US Classification:
435325
Abstract:
Two novel diacylglycerol kinase (DGK) isoforms are disclosed. The cDNA of one DGK isoform, designated DGK. epsilon. , is about 2. 6 kb in length. The DGK. epsilon. cDNA has an open reading frame encoding 567 amino acids and has a predicted molecular mass of 63 kDA. DAG kinase. epsilon. is highly selective for arachidonate-containing diacylglycerol (DAG) substrates. The cDNA of the second isoform, designated DGK. zeta. , is 3. 5 kb in length. The DGK. zeta. cDNA contains a single large open reading frame encoding a 928-amino acid protein with a predicted molecular mass of 103. 9 kDa. An alternatively spliced muscle specific species of DGK. zeta. , DGK. zeta. -2 is also disclosed and characterized. DGK. zeta. is localized to the nucleus. A lysine-rich region with homology to the MARCKS protein is shown to be necessary and sufficient to confer nuclear localization to DGK. zeta.
Human Cytidine Monophosphate (Cmp) Kinase Cdna
Human Cytidine Monophosphate (Cmp) Kinase Cdna
US Patent:
2005010, May 12, 2005
Filed:
Aug 15, 2001
Appl. No.:
10/362332
Inventors:
Stephen Prescott - Salt Lake City UT, US
A. Pearman - Salt Lake City UT, US
Diana Stafforini - Salt Lake City UT, US
Thomas McIntyre - Salt Lake City UT, US
A. Pearman - Salt Lake City UT, US
Diana Stafforini - Salt Lake City UT, US
Thomas McIntyre - Salt Lake City UT, US
International Classification:
C12Q001/68, C07H021/04, C12N009/12, C12P021/02, C12N005/06
US Classification:
435194000, 435069100, 435320100, 435325000, 435006000, 536023200
Abstract:
The present invention provides the cDNA for a novel nucleoside/nucleotide monophosphate kinase cloned from a human macrophage cDNA library. This kinase is able to phosphorylate UMP and utilize multiple phosphate donors, but has demonstrated a preference for transferring a phosphate from ATP or UTP to cytidine monophosphate (CTP). The kinase is thus referred to as cytidine monophosphate (CMP) kinase. This kinase is shown to be a Mg2+ dependent nucleotide kinase which codes for two ubiquitously transcribed mRNA splice products of 3.2 and 2.0 kb, and has been mapped to chromosome 1, region p32-34.1, a region known to contain other nucleotide modifying enzyme genes.
Method Of Screening For Inhibitors Of Human Fatty Acid-Coa Ligase 4
Method Of Screening For Inhibitors Of Human Fatty Acid-Coa Ligase 4
US Patent:
2006022, Oct 5, 2006
Filed:
Jun 2, 2006
Appl. No.:
11/445723
Inventors:
Stephen Prescott - Salt Lake City UT, US
Yang Cao - Salt Lake City UT, US
Yang Cao - Salt Lake City UT, US
International Classification:
A61K 48/00, A61K 31/192, G01N 33/574, C12Q 1/68
US Classification:
514044000, 435006000, 435007230, 514569000, 514575000
Abstract:
The present invention provides a method of screening for potential cancer chemotherapeutic and chemopreventive agents which act by modulating the activity of the Fatty Acid-CoA Ligase 4 (FACL4) gene product in humans. This invention also provides methods of administering such agents to treat cancer by inhibiting the activity of the FACL4 gene product, thus raising the cellular level of free arachidonic acid and triggering arachidonic acid-mediated apoptosis. The present invention further provides a method for diagnosing cancers, including colon cancer.